An AI-powered MRI radiomic model accurately predicted disease-free survival in osteosarcoma, outperforming traditional prognostic factors, according to BMC Medicine. Developed across 14 tertiary centers, it achieved areas under the curve up to 0.916 and maintained strong performance across test sets and chemotherapy subgroups. Radiomic features correlated with tumor immune biomarkers such as CD3, CD8, and CD8/FOXP3 ratio, confirming biological interpretability. Researchers called for further validation in diverse populations and exploration of hypoxia-related markers like HIF-1α.

Source: BMC Medicine